Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.56 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941654 | 0.92 | PTGS2 (0.56) | PTGS2PTGS1HTTSMN1; SMN2LMNA | |
| SCHEMBL7359540 | 0.90 | SOS1 (0.64) | PTGS2PTGS1SOS1HTTSMN1; SMN2 | |
| SCHEMBL1687503 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL8770202 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL11547843 | 0.85 | HTT (0.58) | PTGS2PTGS1SOS1HTTSMN1; SMN2 | |
| SCHEMBL17287077 | 0.85 | HTT (0.68) | PTGS2PTGS1SOS1HTTSMN1; SMN2 | |
| SCHEMBL8941534 | 0.85 | HTT (0.68) | PTGS2PTGS1SOS1HTTSMN1; SMN2 | |
| SCHEMBL2758532 | 0.85 | PTGS2 (0.58) | PTGS2PTGS1HTTSMN1; SMN2 | |
| SCHEMBL14097069 | 0.85 | PTGS2 (0.65) | PTGS2PTGS1 | |
| SCHEMBL12708896 | 0.85 | PTGS2 (0.58) | PTGS2PTGS1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480568-A | FOR LUBRICATING METAL CONTAINING SURFACES | THE DOW CHEMICAL COMPANY (US) | 1996-01-02 | — | — | US | claimed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | PTGS2 1321/4885PTGS1 903/4885SOS1 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.